Have you ever wondered what it feels like to get a minor hurt and have ounces of blood flowing out of the wound? Or have internal bleeding in your knee joint and be not able to do anything about? That is exactly what Hemophilia feels like. Hemophilia is the helpless state where your body gives up on you and your blood doesn’t clot at the right time. The unstoppable blood flow inside or outside the body, is very painful and unbearable at times. Sadly, Hemophilia doesn’t have a cure, leaving the victims with treatment and hemophilia management as the only choice.
Hemophilia is Genetic, ‘X’ chromosome linked recessive disorder that stops the formation of Clotting Factors and in turn, inhibiting the blood from clotting normally. On the basis of the clotting factor, Hemophilia can be classified into three types, represented by alphabets – A, B and C. Hemophilia A is the most common among three where the body doesn’t have enough of Clotting Factor VIII. According to NHLBI, 8 out of 10 people with hemophilia have hemophilia A. Hemophilia B is where there is a lack of Clotting Factor IX. Hemophilia A and B can both be seen in Males victims at higher ratios, and Females are generally either carriers or mildly affected. Though Hemophilia is less common, it is found due to not enough Clotting Factor XI and occurs in both sexes equally. Para-hemophilia is due to not enough Clotting Factor V which is very rare and less commonly known.
Hemophilia has no cure as of today and patients rely completely on treatment and prevention of the disorder. The symptoms of Hemophilia include excessive and prolonged bleeding after an injury, easy bruising or scarring, swollen joints and increased risk of internal or brain hemorrhages and blood in urine and stool. The excessive bleeding episodes, both internal and external are commonly called “Bleeds” and cannot be avoided by the patient. Mild to normal episodes are dealt with slow injection of the hormone desmopressin (DDAVP) into a vein. DDAVP is occasionally given as a nasal medication. In moderate to severe episodes, bleeding may stop only after an infusion of recombinant clotting factor or clotting factor derived from donated human blood. Repeated infusions may be needed if internal bleeding is severe. It is estimated that 80% of the Hemophilia patients suffer from Severe Type of the disorder but unfortunately, only 75% of the patients receive adequate treatment for this chronic disease.
With the population of the world growing at an increasing rate, the prevalence of hemophilia is also increasing. Governments and Healthcare NGO’s have all identified the threat of hemophilia and are taking great steps in spreading awareness and conducting health check-ups to find and diagnose the patients. Preventing Hemophilia in new born babies when the either of the parent is a patient or carrier, is a complex process. The woman’s egg is taken, fertilized with the male sperm and then the embryo is tested for trait before putting it back into the uterus. Normal treatment is done by replacing the missing blood clotting factors in the blood through transfusion or injection. About 20% of the patients develop Antibodies against the foreign clotting factors, which can make the treatment process very difficult.
Growing awareness about the disease and recent advancements in the Gene Therapy have opened the doors to infinite market opportunities. Analysts at Market Data Forecast have analyzed the complex data of this market and have estimated the current Hemophilia Management Market at USD 5.18 billion. It is expected to grow to USD 5.61 billion at a CAGR of 1.62%. Lack of proper awareness about the disease, improper diagnostic mechanisms and high cost of treatment are inhibiting the growth of this market. Major players like Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma and Swedish Orphan Biovitrum AB have identified the problems and opportunities of this market and are forming new strategies to capture the market.
Currently, North America is the largest market for hemophilia management due to high government support and the increasing number of patients suffering from hemophilia, followed by Europe. Asia-Pacific region is estimated to be the fastest growing region owing to its high population base and increasing healthcare expenditure. Recent support from Local Governments in South America show lucrative opportunities in the Latin American Market. Want to know more about the Hemophilia Management Market – Get the insightful Market Research Report by Market Data Forecast today. Grab a Free Report Sample here. To get all the latest updates regarding the Healthcare Market, follow our Blog and subscribe to our Newsletter.